Lilly advances neuroscience portfolio with $7.8bn acquisition of Centessa

CE2026-04-01T12:42:00

Source:

Acquisition includes a potential best-in-class asset for excessive daytime sleepiness, broadening Lilly’s capabilities into sleep medicine.

Eli Lilly is acquiring biotech Centessa Pharmaceuticals for approximately $6.3 billion, a deal that’s set to support advancement of a multiple orexin receptor 2 (OX2R) agonists for sleep-wake disorders.

A further $1.5 billion contingent value right (CVR) payment is on offer to shareholders, subject to achievement of three specified milestones.

Through the agreement, Lilly gains access to

Already a member? Sign-in

Unlock

Driving innovation in pharma manufacturing

European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member